Last updated: 2026-10-07 15:28:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Lakewood-Amedex Biotherapeutics Inc. (LABT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.84, with a market capitalization of $2.03M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.74 to $98.20. This page covers its latest market performance, valuation, price trends and company information.
$2.03M | |
$0.78 | |
$98.20 | |
$0.74 | |
$0.87 | |
7.82M | |
2.40M | |
-- | |
$98.20 | |
$0.74 | |
-- | |
-- |
Lakewood-Amedex Biotherapeutics Inc. (LABT) is currently trading at $0.84 as of 2026-10-07 15:27:00, down 3.23% ($0.03) from the previous close of $0.87
During today's regular trading session, LABT has traded between $0.74 and $98.20, with a trading volume of 7.82M shares. The current price is near the lower end of today's range.
Over the past seven days, Lakewood-Amedex Biotherapeutics Inc. (LABT) moved from $1.15 to $0.84, representing a decline of 27.04% ($0.31).
The stock traded between $0.74 and $2.13 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 5.40 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.1%
LABT is currently trading at $0.84, placing it 0.1% of the way from its 52-week low of $0.74 to its 52-week high of $98.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lakewood-Amedex Biotherapeutics Inc. (LABT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.